Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination
Date
2017-11-01Author
Subject
Metadata
Show full item recordAbstract
The competitive pressure from non-vaccine serotypes may have helped pneumococcal conjugate vaccines (PCVs) to limit vaccine-type (VT) serotype prevalence. We aimed to investigate if, consequently, the indirect protection of vaccines targeting most pneumococcal serotypes could fall short of the profound effects of current formulations. We compared three previously described pneumococcal models harmonized to simulate 20 serotypes with a combined pre-vaccination prevalence in children younger than 5-years-old of 40%. We simulated vaccines of increasing valency by adding serotypes in order of their competitiveness and explored their ability to reduce VT carriage by 95% within 10 years after introduction. All models predicted that additional valency will reduce indirect vaccine effects and hence the overall vaccine impact on carriage both in children and adults. Consequently, the minimal effective coverage (efficacy against carriage×vaccine coverage) needed to eliminate VT carriage increased with increasing valency. One model predicted this effect to be modest, while the other two predicted that high-valency vaccines may struggle to eliminate VT pneumococci unless vaccine efficacy against carriage can be substantially improved. Similar results were obtained when settings of higher transmission intensity and different PCV formulations were explored. Failure to eliminate carriage as a result of increased valency could lead to overall decreased impact of vaccination if the disease burden caused by the added serotypes is low. Hence, a comparison of vaccine formulations of varying valency, and pan-valent formulations in particular, should consider the invasiveness of targeted serotypes, as well as efficacy against carriage.
Description
Collections
Publisher
Place of Publication
Journal
Volume
Issue
Pagination
Author URL
Recommended, similar items
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
Development of a conditionally-attenuated cytomegalovirus (CMV) vaccine vector platform, and initial investigations into use of CMV as a vaccine against pandemic influenza A virus
Hama Salih, Shirin (University of Plymouth, 2017)Abstract Cytomegalovirus (CMV)-based vectors are a promising vaccine platform with an ability to induce high levels of durable, immediate, effector memory T (TEM) cell responses against their heterologous encoded pathogen ... -
Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study
Tsang, RSM; Joy, M; Byford, R; Robertson, C; Anand, SN; Hinton, W; Mayor, N; Kar, D; Williams, J; Victor, W; Akbari, A; Bradley, DT; Murphy, S; O’Reilly, D; Owen, RK; Chuter, A; Beggs, J; Howsam, G; Sheikh, A; Hobbs, FDR; de Lusignan, S (European Centre for Disease Control and Prevention (ECDC), 2023-01-19)<jats:sec> <jats:title>Background</jats:title> <jats:p>Post-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following ... -
Self-disseminating vaccines for emerging infectious diseases
Murphy, Aisling; Redwood, AJ; Jarvis, Michael A (Informa UK LimitedEngland, 2016-01-02)Modern human activity fueled by economic development is profoundly altering our relationship with microorganisms. This altered interaction with microbes is believed to be the major driving force behind the increased rate ...